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The aim of this work was to evaluate in vitro the eﬀect of autologous plasma lipoprotein subfractions on erythrocyte tendency to
aggregate. Aliquots of human blood samples were enriched or not (control) with their own HDL-C, LDL-C, or VLDL-C fractions
obtained from the same batch by density gradient ultracentrifugation. Plasma osmolality and erythrocyte aggregation index (EAI)
weredetermined.BloodaliquotsenrichedwithLDL-CandHDL-CshowedsigniﬁcanthigherEAIthanuntreatedaliquots,whereas
enrichment with VLDL-C does not induce signiﬁcant EAI changes. For the same range of lipoprotein concentrations expressed as
percentage of osmolality variation, the EAI variation was positive and higher in presence of HDL-C than upon enrichment with
LDL-C (P<0.01). Particle size, up to LDL diameter values, seems to reinforce erythrocyte tendency to aggregate at the same
plasma osmolality (particle number) range of values.
1.Introduction
There is scientiﬁc agreement that a high serum level of low-
density lipoproteins cholesterol (LDL-C) is a risk factor for
atherosclerosis and cardiovascular diseases [1–3]. A linear
relationship between LDL-C levels and the occurrence of
coronary artery disease is well documented in two meta-
analysis [4, 5]. Conversely, it has been shown that HDL-
C when at normal or high serum levels acts as a vascular
protector and consequently without contribution such as a
risk factor for atherosclerosis [6]. However, if its antioxidant
capacity is diminished in patients with systolic heart failure,
it will predict a higher risk of incident long term for adverse
cardiac events [7].
Several clinical studies evidenced associations between
complex lipid macromolecules; for example, high LDL-C
concentrations and blood rheological behaviour, like blood
hyperviscosity, that are both referred to as cardiovascular
risk factors [8–10]. Blood viscosity is dependent on macro-
(hematocrit and plasma viscosity) and micro-(erythrocyte
deformability and aggregation) hemorheological parame-
ters. Disturbances in blood rheological behaviour, such as
high values of the blood and plasma viscosity and increased
erythrocyte aggregation tendency, have been described in
patients with ischemic heart diseases [11]. Red blood cells
(RBCs) participate in acute coronary occlusion, mainly
under conditions of lower shear rate, for example, within the
microcirculation in the peri-infarct domain of myocardium
[12].
Under in vitro stasis conditions, RBCs in normal human
blood form loose aggregates with a characteristic morphol-
ogy, similar to a stack of coins. Such aggregationis frequently
named as rouleaux formation [13]. After prolonged stases,
individual rouleaux can cluster, thereby forming three-
dimensional structures, [14, 15]. Under circulation, the
attractive forces involved are relatively weak, and aggregates
can be dispersed during ﬂow by the shear rate [16].
RBCs aggregation increasing at low shear rate aﬀects blood
viscosity and microvascular ﬂow dynamics being markedly
enhanced in several clinical states [17–21].2 Biochemistry Research International
Factors inﬂuencing RBCs aggregation can be divided
into (i) extrinsic factors such as levels of plasma pro-
teins (e.g., ﬁbrinogen, lipoproteins, macroglobulins, or
immunoglobulins), hematocrit, and shear rate, and (ii)
intrinsic factors, for example, RBCs shape, deformability
and membrane surface properties [22–32]. RBC membrane
surface properties and structure, such as surface charge and
the ability of macromolecules to penetrate the membrane
glycocalyx, greatly aﬀect aggregation for cells suspended in a
deﬁned medium [33, 34]. Diﬀerent studies have shown that
hyperlipoproteinemia is associated with erythrocyte hyper-
aggregation [35–37]. The inverse correlation of erythrocyte
aggregation with HDL2-C subfraction was reported in
hypercholesterolemia middle-aged male population without
apparentsymptomsofcardiovasculardisease[38].Itwasevi-
denced in vitro that LDL-C enhances the RBCs aggregation
induced by ﬁbrinogen according to two aggregation models
[39]. Considering the particle-like nature of the lipoproteins
weraisethehypothesisthatincreasedamountsoflipoprotein
particles may change plasma osmolality with repercussions
in erythrocyte aggregation.
The aim of our work was to study in vitro the erythro-
cyte aggregation tendency in blood samples collected from
healthy male adults and enriched with their own plasma
lipoproteins subfractions.
2.MaterialandMethods
2.1. Blood Samples. On consecutive days, venous blood
samples were obtained with previous consent from healthy
fasting volunteers adult males (n = 10) after 15min in the
recumbentpositionandcollected(fortwoplastictubes)with
anticoagulant (10 I.U. of heparin/mL or 0.1% EDTA).
2.2. Lipoprotein Fractions. Lipoproteins fractions were pre-
pared by a discontinuous NaCl/KBr density gradient ultra-
centrifugation using an SW 50.1 rotor (Beckman) [40].
Lipoprotein fractions were characterised by electrophore-
sis (Electra HR Helena Laboratories) buﬀer tris-barbital-
sodium buﬀer pH 8.8) in cellulose acetate by comparison
with serum controls (Lipotrol, Helena Laboratories).
2.3. Erythrocyte Aggregation Index. Erythrocyte aggregation
was determined using the MA1 aggregometer from Myrenne
GMBH (Roetgen, Germany). The MA1 aggregometer con-
sists of a rotating cone plate chamber which disperses the
sample by high shear rate of 600s−1 and a photometer
that determines the extent of aggregation. The intensity of
light (emitted by a light emitting diode) is measured after
transmissionthroughthebloodsample.Theaggregationwas
determined in stasis for 10 seconds after dispersion of the
blood sample [41].
2.4. Plasma Osmolality. Plasma osmolality was determined
with the Osmomat 030 Cryoscopic Osmometer from
Gonotec (Berlin, Germany).
2.5. Experimental Design. Blood samples from each donor
were divided on aliquots, and after centrifugation and
small volumes of plasma (0, 5μL, 10μL, 20μL, and 40μL)
were discharged and replaced by equal values of their own
previously enriched lipoprotein subfractions prepared a day
before. With this procedure, no hematocrit variations were
obtained. Blood aliquots were gently mixed by inversion,
and erythrocyte aggregation was assessed. At the end of
each assay, the aliquots were centrifuged at 12000rpm for
1 minute in the Biofuge 15 centrifuge from Heraeus, and
plasma osmolality was determined. HDL-C, LDL-C, and
VLDL-C concentrations were expressed as percentage of
osmolality variation values.
2.6. Statistical Analysis. The statistical evaluation performed
utilized the “one-way” ANOVA with homogeneity test,
cluster analysis, and average method.
3. Results
The major plasma lipoprotein subfractions were obtained by
the discontinuous density gradient centrifugation between
the density range of 1.006 and 1.300g/mL. Each lipoprotein
fraction was well banded with VLDL-C at the top, LDL-C
in the upper middle and the HDL-C in the lower middle
portion of the tube. After that, each fraction was pooled and
submitted to electrophoresis where their obtained migration
was conﬁrmed by comparison with the serum control.
The volume of each lipoprotein sub-fraction added to
the autologous blood samples aliquots caused variation of
osmolality concentrations in relation to its absence. Using
the cluster analysis and the beverage method, four classes
of concentration range expressed as osmolality variation
were grouped for each LDL-C; the VLDL-C and the HDL-C
enriched blood aliquots, namely, Class I 0.005–0.025; Class
II 0.030–0.035; Class III 0.045–0.055; Class IV 0.077–0.095
(Figure 1).
The erythrocyte aggregation variation for each enriched
LDL,HDL,andVLDLblood aliquotsinrelationtotheinitial
value is grouped by the diﬀerent osmolality class variation
values (Figure 2). The variation of erythrocyte aggregation
in relation to the initial values depends on the plasma
osmolality values, as well as of the type of lipoprotein sub-
fraction. The enriched VLDL-C blood samples aliquots do
not induce statistical signiﬁcant variation on erythrocyte
aggregation values (Figure 3). At variance in relation to the
initial erythrocyte aggregation values, the enriched LDL-
C blood samples presented signiﬁcant statistical enhanced
values at all range of percentage of osmolality variation
(Figure 4). The same behaviour was veriﬁed in the enriched
HDL-C blood aliquots, with exception for the higher values
of percentages of osmolality variation, where a very signiﬁ-
cant (P<0.0001) decrease was obtained for the erythrocyte
aggregation (Figure 5). For the same range of osmolality
variation, the two types of lipoproteins LDL-C and HDL-
C induced diﬀerent variation of erythrocyte aggregation
(P<0.01). When the values of osmolality variation were
plotted against the respective values of aggregation variationBiochemistry Research International 3
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Figure 1: Histogram presenting the concentrations of enriched
blood samples with LDL-C (red), HDL-C (blue), VLDL-C (green)
distributed by four classes according the osmolality scale of values
(class I 0.005–0.025; class II 0.030–0.035: class III 0.045–0.055; class
IV 0.077–0.095).
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Figure 2: Histogram presenting the values of the erythrocyte
aggregation variation obtained in enriched blood samples with
LDL-C (red), HDL-C (blue), VLDL-C (green) in the four classes
of concentration according the osmolality scale of values (I 0.005–
0.025; II 0.030–0.035: III 0.045–0.055; IV 0.077–0.095).
obtainedineachenrichedHDL-Caliquot,asigniﬁcant(R2 =
0.383) inverse linear regression was obtained (Figure 6).
4. Discussion
In the present in vitro study, we investigated the induction of
human erythrocyte tendency to aggregation by autologous
lipoproteins sub-fractions. With the amount of lipoprotein
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Figure 3: Values of erythrocyte aggregation index (mean +/– sd)
obtained in enriched blood samples with HDL-C and without
enrichment.
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Figure 4: Values of erythrocyte aggregation index (mean +/– sd)
obtained in enriched blood samples with HDL-C and without
enrichment
sub-fractions added, changes in plasma osmolality were
observed as a consequence of the increase number of
particles. We used cluster method on the values of osmolality
to deﬁne four classes (Figure 1).
In blood aliquots enriched with VLDL-C, no changes
in erythrocyte aggregation index were veriﬁed (Figure 3).
For the same amount of particles corresponding to the
same class of osmolality variation, both HDL-C and LDL-C
enrichment induce enhancement of erythrocyte aggregation
(Figures 4 and 5). VLDL has higher diameter than the other
twolipoprotein classes[42]andmayeitherrestin theplasma
bulk not interfering with erythrocyte aggregation tendency.
LDL-C particles bind in a nonabsolute speciﬁc way with
erythrocyte membrane, while 60% of membrane area can be
occupied by HDL-C as has been described [43]. The occu-
pancy of some areas of erythrocyte membrane by HDL-C or
LDL-C, causing some interference in the promotion of EAI
tendency, may be an explanation for our results. Signiﬁcant
(P<0.01) higher values of erythrocyte aggregation were
obtained in HDL-C-enriched aliquots more than for LDL-
C-enriched ones at the same class of osmolality variation
(under the same number of particles). The exception was4 Biochemistry Research International
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Figure 5: Values of erythrocyte aggregation index (mean +/– sd)
obtained in enriched blood samples with LDL-C and without
enrichment.
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Figure 6: Presentation of the association obtained between the ery-
throcyte aggregation values and the osmolality values in enriched
blood sample with HDL-C.
fortheHDL-C-enrichedaliquotswiththehighestpercentage
of osmolality variation which signiﬁcantly (P<0.0001)
decreased EAI to lower values than the aliquot control
obtained. We raise the hypothesis that the higher number of
unbinding HDL-C particles may increase the ionic strength
to a threshold and consequently pull away the erythrocytes
decreasing their tendency to aggregate.
Our results suggest that in healthy human blood aliquots
enriched with autologous HDL-C or LDL-C, (where ﬁbrino-
genispresentatnormalrange),whensubmittedtoshearrate
to disaggregate RBCs, and stopped after that, EAI tendency
increases. The association between EAI values and HDL-C
obtained in our experimental design is in accordance with
othersstudies[39],whichisadecreaseofﬁbrinogen-induced
RBCs aggregation in presence of the HDL2 subclass as not
observed in a diﬀerent experimental approach.
Recently [44], it was veriﬁed that the LDL particles num-
bermustbeconsideredasanindicatorforatherosclerosisrisk
factor, which has been previously remembered by others in
the prevention of cardiovascular disease [45].
Two models, the cross-bridging and the depletion layer,
were described to explain the reversible erythrocyte aggre-
gation process at physiological conditions [46], but there
are controversies and diﬃc u l t i e st oa d o p to n eo rr e j e c ta n
other. The depletion model developed for polymer solutions
of dextran demonstrated that there is an optimal molecular
weight value to reach the greater erythrocyte aggregation
tendency [47]. The hydrodynamic radius (Rh) determined
for VLDL [48] is in the range between 15nm and 40nm
which is much above of others belonging to macromolecules
promoters of erythrocyte aggregation increase [49]. Particle
size is an inﬂuent factor that may explain the absence
of VLDL eﬀect in the erythrocyte aggregation obtained.
Regarding our results, they may also ﬁt the cross-bridging
model if, by an unknown mechanism, we assume that the
particles numbers and size favour ﬁbrinogen binding in
a similar way as previously reported for immunoglobulin
eﬀects on ﬁbrinogen-mediated erythrocyte aggregation [50,
51]. More studies are needed to explain in what model ﬁt the
eﬀectsof lipoproteins in erythrocyte aggregation. Ourresults
may contribute to better understand the direct associations
between high erythrocyte aggregation tendency and other
cardiovascular risk factors such as hyperlipoproteinemia.
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